KR920011489A - 세로토닌 길항제 - Google Patents

세로토닌 길항제 Download PDF

Info

Publication number
KR920011489A
KR920011489A KR1019910023435A KR910023435A KR920011489A KR 920011489 A KR920011489 A KR 920011489A KR 1019910023435 A KR1019910023435 A KR 1019910023435A KR 910023435 A KR910023435 A KR 910023435A KR 920011489 A KR920011489 A KR 920011489A
Authority
KR
South Korea
Prior art keywords
formula
alkyl
compound
hydrogen
general formula
Prior art date
Application number
KR1019910023435A
Other languages
English (en)
Inventor
케이트 딕슨 아놀드
칼 안드레아스 기거 루돌프
Original Assignee
진 크래머, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909027425A external-priority patent/GB9027425D0/en
Priority claimed from GB909027424A external-priority patent/GB9027424D0/en
Priority claimed from GB919113596A external-priority patent/GB9113596D0/en
Application filed by 진 크래머, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 진 크래머, 한스 루돌프 하우스
Publication of KR920011489A publication Critical patent/KR920011489A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

세로토닌 길항제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 약학적 캐리어 또는 부형제와 함께 유리형태이거나 약학적으로 허용가능한 염 또는 복합체 형태의 하기 일반식(Ⅰ)의 화합물을 포함하는 약학적 조성물：
    상기식에서, R1은 알킬(1-4C), R2는 수소, 알킬(-7C), 알케닐(3-6C), 알키닐(3-10C), 시클로알킬(3-7C), 시클로알킬(3-7C), 알킬(1-4C), 페닐, 페닐알킬(1-3C), 알킬(1-6C)카르보닐, 알킬(1-6C) 옥시카르보닐, 카르바모일, 설파모일 또는 모노-또는 디알킬(1-6C) 카르바모일 또는 -설파모일, X는 CH 또는 N이며, Y는 NR3(여기에서, R3는 수소 또는 알킬(1-6C)이다) 또는 0이거나, X-Y는 C-A-N 또는 C-A-CH(여기에서, A는 CH=CH 또는 -(CH2)이고, m은 2 또는 3), n은 0, 1 또는 2이고, Z는 일반식
    로 표시되거나 또는 R1은 수소, R2, X, Y 및 n은 상기 기재된 바와 동일하며, 그리고 Z도 상기 기재된 바와 동일하나 X가 N일 때 상기 일반식(a)가 아니며, 상기식(a)에서, o은 0, p는 0, 1 또는 2 그리고 q는 0, 1 또는 2이거나, 또는 o은 1, p는 0 그리고 q는 0 또는 1, 그리고 R4는 수소, 알킬(1-7C), 시클로알킬(3-6C) 및 할로겐, 알킬(1-4C) 또는 알콕시(1-4C)에 의해 임의로 단일 또는 이치환된 페닐알킬(1-4C)이고, 식(b)에서 o 은 1, 2 또는 3, p 은 0 또는 1 그리고 q 은 0 또는 1이고, 식(c) 및 (d)에서, R5, R6 및 R7중 한 기는 수소, 알킬(1-6C), 시클로알킬(3-7C), 알케닐(2-6C), 페닐 또는 페닐 알킬(1-3C)이며, 그리고 다른 두 기는 각가 수소 또는 알킬(1-6C)이고, 단 n이 0이며 Y가 NR3또는 (x와 함께) N-A-C 일 때 Z는 (d)가 아니다.
  2. 약학제제로서 사용하기 위한 유리 형태이거나 약학적으로허용 가능한 염 또는 복합체 형태의 제1항에 기재된 일반식(Ⅰ)의 합합물.
  3. (a)하기 일반식(Ⅰa)의 화합물을 생성하기 위해 하기 일반식(Ⅱ)의 화합물 또는 그들의 반응성 유도체를 하기 일반식(Ⅲ)의 화합물과 함께 축합하거나, 또는 (b)하기 일반식(Ⅰb)의 화합물을 생성하기 위해 하기 일반식(Ⅳ)의 화합물을 하기 일반식(Ⅴ)의 화합물을 사용하여 알킬화 하거나, 도는 (c) 일반식(Ⅰ)의 화합물의 어떤 보호된 형태를 탈보호하여 일반식(Ⅰ)의 화합물을 수득하며, 이렇게해서 생성되는 일반식(Ⅰ)의 화합물을 유리형태 또는 염이나 복합체 형태로 회수하는 것을 포함하는 하기일반식(Ⅰ)의 화합물의 생성방법；
    B-(CH2)n-Z (V)
    상기식에서 R1은 알킬(1-4C), 그리고 R2, X, Y, n 및 Z는 제1항에 기재된 바와 동일하거나, 또는 R1은 수소, R2, X, Y 및 n은 제1항에 기재된 바와 동일하며 Z는 제1항에 기재된 일반식(b) 또는 (c)이며, X1은 CH 또는 N, Y1은 NR3또는 O, B는 이탈기 이다.
  4. 유리 형태이거나 염 또는 복합체 형태의 제3항에 기재된 일반식(Ⅰ)의 화합물.
  5. R1은 알킬(1-4C), R2는 수소, x는 CH, Y는 O 또는 NH, n은 O 그리고 Z는 하기일반식(a )인 제3항에 기재된 일반식(Ⅰ)의 화합물：
    상기식에서, R´4는 메틸, 에틸 또는 프로필이며 q ″는 0, 1 또는 2이다.
  6. 유리 형태이거나 염 또는 복합체 형태의 7-메톡시-1H-인돌-3-카르복실산-(1αH, 5αH)-8-메틸-8-아자-비시클로 [3, 2, 1]옥트-3α-일-에스테르인 제3항에 기재된 일반식(Ⅰ)의 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910023435A 1990-12-18 1991-12-17 세로토닌 길항제 KR920011489A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB909027425A GB9027425D0 (en) 1990-12-18 1990-12-18 Improvements in or relating to organic compounds
GB9027425 1990-12-18
GB909027424A GB9027424D0 (en) 1990-12-18 1990-12-18 Improvements in or relating to organic compounds
GB9027424 1990-12-18
GB919113596A GB9113596D0 (en) 1991-06-24 1991-06-24 Improvements in or relating to organic compounds
GB9113596 1991-06-24

Publications (1)

Publication Number Publication Date
KR920011489A true KR920011489A (ko) 1992-07-24

Family

ID=27265408

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910023435A KR920011489A (ko) 1990-12-18 1991-12-17 세로토닌 길항제

Country Status (22)

Country Link
US (2) US5272154A (ko)
EP (1) EP0491664B1 (ko)
JP (1) JP2740777B2 (ko)
KR (1) KR920011489A (ko)
AT (1) ATE163648T1 (ko)
AU (1) AU651640B2 (ko)
CA (1) CA2057391A1 (ko)
CZ (1) CZ280647B6 (ko)
DE (1) DE69129009T2 (ko)
DK (1) DK0491664T3 (ko)
ES (1) ES2113368T3 (ko)
FI (1) FI102069B1 (ko)
GR (1) GR3026506T3 (ko)
HU (1) HU211081B (ko)
IE (1) IE914387A1 (ko)
IL (1) IL100384A (ko)
MX (1) MX9102582A (ko)
MY (1) MY109983A (ko)
NZ (1) NZ240993A (ko)
PT (1) PT99829B (ko)
SG (1) SG47026A1 (ko)
SK (1) SK278597B6 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004347A1 (fr) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Derive d'indole et medicament
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
EP1425286B1 (en) * 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
IL160884A0 (en) 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
BR0214016A (pt) 2001-11-09 2004-10-13 Upjohn Co Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
JP2005523288A (ja) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
BR0315056A (pt) * 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
DE602004010299T2 (de) * 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
AU2005227324A1 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
EP1742944B1 (en) * 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
NZ551712A (en) * 2004-05-07 2010-07-30 Memory Pharm Corp 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparations and uses thereof
WO2006052640A1 (en) * 2004-11-05 2006-05-18 Theravance, Inc. 5-ht4 receptor agonist compounds
ES2327142T3 (es) * 2004-11-05 2009-10-26 Theravance, Inc. Compuestos de quinolinona-carboxamida.
AU2005319248A1 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
NZ555180A (en) * 2004-12-22 2010-09-30 Theravance Inc Indazole-carboxamide compounds useful as 5-HT4 receptor agonists
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8114891B2 (en) 2007-10-01 2012-02-14 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
PL3201203T3 (pl) 2014-09-29 2021-11-22 Takeda Pharmaceutical Company Limited Krystaliczna postać 1-(1-metylo-1h-pirazol-4-ilo)-n-((1r,5s,7s)-9-metylo-3-oksa-9-azabicyklo[3.3.1]nonan-7-ylo)-1h-indolo-3-karboksyamidu

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
EP0189002B1 (en) * 1984-12-20 1993-03-03 Sandoz Ag Treatment of gastrointestinal disorders using 5-ht3 antagonists
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
GB8623142D0 (en) * 1986-09-26 1986-10-29 Beecham Group Plc Compounds
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
US4859662A (en) * 1986-11-28 1989-08-22 Glaxo Group Limited Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
DE3752062T2 (de) * 1986-12-17 1997-09-11 Glaxo Group Ltd Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
GB8720693D0 (en) * 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
EP0317088A1 (en) * 1987-10-22 1989-05-24 Glaxo Group Limited Ketone derivatives
DE3872872T2 (de) * 1987-11-14 1993-02-04 Beecham Group Plc 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
DE3810552A1 (de) * 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US4985422A (en) * 1988-04-27 1991-01-15 Glaxo Group Limited Lactam derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
ES2088389T3 (es) * 1988-08-02 1996-08-16 Glaxo Group Ltd Derivados de lactamas.
FR2639944B1 (fr) * 1988-12-06 1991-01-18 Adir Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
NZ233285A (en) * 1989-04-18 1992-06-25 Duphar Int Res Imidazole-substituted carbamoyl-indoles and condensed analogues thereof and pharmaceutical compositions
GB8916682D0 (en) * 1989-07-21 1989-09-06 Beecham Group Plc Pharmaceutical compounds

Also Published As

Publication number Publication date
DK0491664T3 (da) 1998-09-28
FI915920A (fi) 1992-06-19
CS381591A3 (en) 1992-07-15
DE69129009D1 (de) 1998-04-09
FI915920A0 (fi) 1991-12-16
NZ240993A (en) 1994-08-26
ATE163648T1 (de) 1998-03-15
FI102069B (fi) 1998-10-15
FI102069B1 (fi) 1998-10-15
JP2740777B2 (ja) 1998-04-15
ES2113368T3 (es) 1998-05-01
CA2057391A1 (en) 1992-06-19
AU651640B2 (en) 1994-07-28
EP0491664A1 (en) 1992-06-24
PT99829B (pt) 2000-08-31
SG47026A1 (en) 1998-03-20
HU913792D0 (en) 1992-02-28
DE69129009T2 (de) 1998-07-23
IE914387A1 (en) 1992-07-01
IL100384A0 (en) 1992-09-06
HUT61543A (en) 1993-01-28
AU8979191A (en) 1992-06-25
MY109983A (en) 1997-10-31
IL100384A (en) 1996-05-14
PT99829A (pt) 1992-12-31
US5543426A (en) 1996-08-06
MX9102582A (es) 1993-01-01
US5272154A (en) 1993-12-21
JPH04308590A (ja) 1992-10-30
EP0491664B1 (en) 1998-03-04
GR3026506T3 (en) 1998-07-31
CZ280647B6 (cs) 1996-03-13
HU211081B (en) 1995-10-30
SK278597B6 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
KR920011489A (ko) 세로토닌 길항제
GB8919434D0 (en) Novel compounds
TW385309B (en) Novel thiazolidinedione antidiabetic agents
KR920014803A (ko) 인돌 유도체
WO1996013512B1 (en) L-ribofuranosyl nucleosides
KR920021535A (ko) 다환 아민 화합물 및 그의 거울상 이성질체, 그의 제조방법 및 이를 함유하는 제약학적 조성물
NL300107I2 (nl) Toepassing van adamantaan-derivaten voor het voorkomen en de behandeling van cerebrale ischemie.
GB8919417D0 (en) Novel compounds
PT89623B (pt) Processo de preparacao de derivados de indolcarbazolo e de composicoes farmaceuticas contendo esses compostos
KR920000724A (ko) 2,4- 및 2, 5-치환된 피리딘-n-옥사이드, 이의 제조방법 및 이의 용도
KR920019746A (ko) 신규한 시클로헥실벤즈아미드 유도체, 그의 제조방법 및 약제로서의 용도
KR910019975A (ko) 인돌 유도체
ATE73790T1 (de) Amino 5,6,7,8tetrahydronaphtho(2,3b&gt;furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES8800142A1 (es) Un procedimiento para preparar un derivado de semicarbazida
KR890017244A (ko) 6-페닐-3-(피페라지닐알킬)-2,4-(1h,3h)-피리미딘디온 유도체, 그의 제법 및 치료에의 이용
ZA889023B (en) 2-(piperazinyl)-2-oxoethylene substituted flavonoid derivatives,processes for preparing them and pharmaceutical compositions containing them
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
KR930006003A (ko) 이미다졸릴메틸-피리딘류 화합물
KR930002353A (ko) 6-옥소 아제피노 인돌 화합물과 이의 제조방법 및 이들의 제조를 위한 중간화합물과 이 화합물을 포함하는 약제
GB1180164A (en) Dibenzazepine Derivatives and their preparation
KR890014561A (ko) 세펨 화합물 및 이의 제조방법
ES8407052A1 (es) Procedimiento para la preparacion de nuevas tienobenzodiazepinonas sustituidas
KR870011134A (ko) 에트골린 에스테르 및 이의 제조방법
GR3020292T3 (en) Use of 2-iminothiazolidin-4-one derivatives as new medicaments
ES8202003A1 (es) Un procedimiento para la preparacion de derivados de ergoli-na

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application